학술논문
Post-COVID syndrome, inflammation, and diabetes.
Document Type
Academic Journal
Author
Rizvi, Ali A.; Kathuria, Amita; Al Mahmeed, Wael; Al-Rasadi, Khalid; Al-Alawi, Kamila; Banach, Maciej; Banerjee, Yajnavalka; Ceriello, Antonio; Cesur, Mustafa; Cosentino, Francesco; Galia, Massimo; Goh, Su-Yen; Janez, Andrej; Kalra, Sanjay; Kempler, Peter; Lessan, Nader; Lotufo, Paulo; Papanas, Nikolaos; Santos, Raul D.; Stoian, Anca P.; et al
Source
Subject
Language
English
ISSN
1056-8727
Abstract
The raging COVID-19 pandemic is in its third year of global impact. The SARS CoV 2 virus has a high rate of spread, protean manifestations, and a high morbidity and mortality in individuals with predisposing risk factors. The pathophysiologic mechanisms involve a heightened systemic inflammatory state, cardiometabolic derangements, and varying degrees of glucose intolerance. The latter can be evident as significant hyperglycemia leading to new-onset diabetes or worsening of preexisting disease. Unfortunately, the clinical course beyond the acute phase of the illness may persist in the form of a variety of symptoms that together form the so-called "Long COVID" or "Post-COVID Syndrome". It is thought that a chronic, low-grade inflammatory and immunologic state persists during this phase, which may last for weeks or months. Although numerous insights have been gained into COVID-related hyperglycemia and diabetes, its prediction, course, and management remain to be fully elucidated.